Holen Sie sich die Stockscreener-App
10.50
6.75%
-0.76
Schlusskurs vom Vortag:
$11.26
Offen:
$11.4
24-Stunden-Volumen:
2.21M
Relative Volume:
1.70
Marktkapitalisierung:
$895.79M
Einnahmen:
$42.95M
Nettoeinkommen (Verlust:
$-130.01M
KGV:
-6.4504
EPS:
-1.6278
Netto-Cashflow:
$-19.66M
1W Leistung:
-10.79%
1M Leistung:
-26.16%
6M Leistung:
-38.56%
1J Leistung:
+37.61%
1-Tages-Spanne:
$10.32
$11.40
1-Wochen-Bereich:
$10.32
$12.26
52-Wochen-Spanne:
$7.235
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
10.50 | 1.00B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6%What's Next? - MarketBeat
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease - Benzinga
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk - Investing News Network
Monte Rosa Therapeutics Announces Positive Phase 1 Results for MRT-8102 in GFORCE-1 Trial - Kalkine Media
Monte Rosa posts trial data for anti-inflammatory drug (GLUE) - Seeking Alpha
Monte Rosa Therapeutics, Inc. (GLUE) Stock Price, News, Quote & History - Yahoo! Finance Canada
An experimental drug brought several heart-disease markers to levels seen in healthy volunteers - Stock Titan
Monte Rosa Therapeutics Shares Surge PremarketMonte Rosa Therapeutics (NASDAQ:GLUE) - Benzinga
Why is Monte Rosa Therapeutics stock surging 20% today? By Investing.com - Investing.com Canada
HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with Buy rating, $25 price target - TradingView
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - uk.finance.yahoo.com
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk - Investing News Network
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Safety and activity data will be presented Oct. 1 for people at elevated heart-disease risk after four weeks of treatment. - Stock Titan
Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE - MarketBeat
(GLUE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
What Monte Rosa Therapeutics (GLUE)'s Phase 2 Trial Start Means For Shareholders - Simply Wall Street
Can Monte Rosa Therapeutics (NASDAQ:GLUE) Rewrite Its Story? - Kalkine Media
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
How (GLUE) Movements Inform Risk Allocation Models - Stock Traders Daily
What’s Behind Monte Rosa Therapeutics (NASDAQ:GLUE) Latest Slide? - Kalkine Media
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 6%What's Next? - MarketBeat
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone - Yahoo Finance
Opaleye Management Inc. Acquires Shares of 745,000 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics at Wells Fargo: pipeline gains and long cash runway - Investing.com Canada
Wellington Management Group LLP Buys 78,635 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Outperform" Rating from Wedbush - MarketBeat
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - moomoo.com
Monte Rosa Earns $50M Milestone Payment as Novartis Starts Phase 2 Trial - Minichart
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 - Investing News Network
Novartis startet Phase-II-Studie mit Wirkstoff von Monte Rosa Therapeutics - TradingView
Monte Rosa earns milestone as MRT-6160 enters Phase 2 - TipRanks
A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial - Stock Titan
Monte Rosa Announces $50M Milestone as Novartis Starts Phase 2 for MRT-6160 in Sjögren’s - TradingView
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) - Yahoo Finance
How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial - webull.com
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
GLUE News | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet - Seeking Alpha
Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
GLUE stock gains on investor conference plans and Monte Rosa outlook - ad-hoc-news.de
Six new hires get stock awards from Monte Rosa - Stock Titan
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Monte Rosa Therapeutics Inc-Aktie (GLUE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Option Exercise |
3.98 |
4,351 |
17,317 |
66,722 |
| Champoux Jennifer | Chief Operating Officer |
Jul 15 '26 |
Sale |
23.38 |
4,351 |
101,730 |
62,371 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):